ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Karsh Discusses Treatment Sequencing in mCRPC

Lawrence Karsh, MD
Published: Friday, May 17, 2013

Lawrence Karsh, MD, director of the Clinical Research Department, at The Urology Center of Colorado, discusses strategies for sequencing the wide array of new agents available to treat men with castration-resistant prostate cancer.

Given the overall lack of data on sequencing, Karsh recommends utilizing practical considerations to determine how to best treat patients. These parameters include patient preference, comorbidities, and financial considerations. Furthermore, he notes, with the overall lack of available guidelines and biomarkers, most patients will likely receive several of the approved therapies.

Lawrence Karsh, MD, director of the Clinical Research Department, at The Urology Center of Colorado, discusses strategies for sequencing the wide array of new agents available to treat men with castration-resistant prostate cancer.

Given the overall lack of data on sequencing, Karsh recommends utilizing practical considerations to determine how to best treat patients. These parameters include patient preference, comorbidities, and financial considerations. Furthermore, he notes, with the overall lack of available guidelines and biomarkers, most patients will likely receive several of the approved therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x